A prospective, single-arm, before-and-after comparative study evaluating the impact of switching from mepolizumab to depemokimab on patient satisfaction, treatment convenience, and quality of life in patients with severe eosinophilic asthma

A prospective, single-arm, pre-post observational study evaluating the impact of switching from mepolizumab to depemokimab on patient-reported outcomes, including treatment satisfaction, convenience, and quality of life, in patients with severe eosinophilic asthma - DeSwitch-PRO Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000061347

Enrollment

Registered

2026-04-22

Start date

2026-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

severe asthma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with severe eosinophilic asthma who are currently receiving outpatient care at Himeji St. Mary's Hospital, St. Francis Society Social Medical Foundation, between the date of study approval and March 31, 2027, and who have been using an IL-5 antibody (mepolizumab) for at least 6 months 2. Patients aged 18 years or older 3. Patients who can provide informed consent to participate in the study of their own free will 4. Patients scheduled to switch to depemokimab

Exclusion criteria

Exclusion criteria: 1. Patients who declined to participate in this study 2. Patients whom the principal investigator deemed unsuitable for this study 3. Patients currently participating in clinical trials of other drugs or medical devices

Design outcomes

Primary

Measure	Time frame
Change from baseline in the TSQM-9 Convenience score at Week 26	—

Secondary

Measure	Time frame
1. Changes in TSQM-9 Global Satisfaction and Effectiveness 2. Changes in ACT and mini-AQLQ scores 3. PGIC assessment 4. Number of asthma exacerbations 5. Changes in FEV1, FeNO, and blood eosinophil count 6. Safety (adverse events) 7. Assessment of treatment retention rate	—

Countries

Japan

Contacts

Public ContactYasuhiro Nakajima

Social Medical Corporation St. Francis Society Himeji St. Mary's Hospital Department of Respiratory Medicine

y0a1s0u7@gmail.com0792655111

Outcome results